| abstract |
Inhibitors of TDO2 expressed by cells and pharmaceutical compositions thereof are provided by the present application. These inhibitors and their pharmaceutical compositions can be used to modulate the activity of tryptophan 2, 3 dioxygenase, to treat immunosuppression, to treat medical conditions that benefit from the inhibition of tryptophan degradation, It is useful to enhance the efficacy of anti-cancer treatments, including administering cancer agents, and to treat tumor-specific immunosuppression associated with cancer. |